Related Experiment Videos
Atenolol and ischaemic heart disease: an overview
1Cardiac Department, Whythenshawe Hospital, Manchester, England.
Insights
Atenolol effectively treats ischaemic heart disease by improving myocardial oxygen supply and demand. This beta-blocker offers life-saving benefits in myocardial infarction and shows promise for other ischaemic conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischaemic heart disease (IHD) management involves various therapeutic agents.
- Beta-blockers and calcium antagonists are commonly used for IHD, but their efficacy varies.
Purpose of the Study:
- To review and compare the efficacy of beta-blockers, specifically atenolol, with calcium antagonists in treating ischaemic heart disease.
- To evaluate the role of atenolol in different IHD scenarios, including acute myocardial infarction.
Main Methods:
- Review of existing data on beta-blocker (atenolol) and calcium antagonist use in IHD.
- Comparison of clinical outcomes and therapeutic benefits reported in the literature.
Main Results:
- Atenolol demonstrates effectiveness in managing ischaemic heart disease, particularly when reduced myocardial oxygen supply or increased demand is implicated.
- Calcium antagonists have shown disappointing and inconsistent results in IHD treatment.
- Atenolol is the only beta-blocker proven to provide life-saving benefits in acute myocardial infarction interventions.
Conclusions:
- Convincing evidence supports the use of atenolol across the spectrum of ischaemic heart disease.
- The cardioprotective effects of atenolol suggest potential applicability to conditions like silent ischaemia.
Abstract:
Data generated to date on the use of beta-blockers, especially atenolol, in ischaemic heart disease are reviewed and compared with the results available with the calcium antagonists. Atenolol appears to be effective as an anti-ischaemic agent in patients with obstructive coronary artery disease when reduction in myocardial oxygen supply (ischaemia not preceded by an increase in heart rate and due presumably to functional coronary stenosis) or increase in demand are the likely causes. Based on current concepts and available data, there is convincing evidence to support the use of atenolol across the spectrum of ischaemic heart disease. In contrast, results with the calcium antagonists have been disappointing and variable. Atenolol, to date, is the only beta-blocker which has been demonstrated to have a life-saving benefit in acute intervention (within 12 hours of onset) in myocardial infarction. This cardioprotective aspect of the drug is likely to be applicable to other areas of ischaemic heart disease, including silent ischaemia.